The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Key considerations for clinicians when treating multiple myeloma with teclistamab
Ariel Grajales-Cruz, MD, Moffitt Cancer Center, Tampa, FL, addresses key clinician considerations when managing multiple myeloma (MM) with teclistamab. The primary cause for concern is the high infection rate seen when treating patients with this agent, which should be anticipated and prevented with appropriate prophylactic measures. Cytokine release syndrome (CRS) and potential neurotoxicity are also concerns which must be considered and managed as necessary to improve patient outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Speakers Bureau: Amgen, Sanofi
Board of Directors/Advisory Committee: Sanofi, Cellectar, Janssen
